Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT

Swanson, Priscilla; Mendoza, Carmen de; Joshi, Yagnya; Golden, Alan; Hodinka, Richard L.; Soriano, Vincent; Devare, Sushil G.; Hackett, John

doi:10.1128/jcm.43.8.3860-3868.2005

Cited by 102 publications

(84 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some less prevalent HIV subtypes may escape detection by PCR (e.g. HIV A, C‐H and O) 14. Those using PCR for diagnosis should know the sensitivity of the assay being used for the likely subtype being tested for.…”

Section: Diagnosis Baseline Investigations and Pretreatment Monitoringmentioning

confidence: 99%

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV‐1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short‐term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long‐term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first‐ and second‐line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

show abstract

Section: Diagnosis Baseline Investigations and Pretreatment Monitoringmentioning

confidence: 99%

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The PVL provide an accurate measure to identify new infections, monitor disease progression and response to ART (Clerici et al, 1997;Ho et al, 1995;Katzenstein and Holodniy, 1995;Wei et al, 1995). Chronic immune activation detected by the co-expression of CD38 and HLA-DR on CD4+ and CD8+ T-cells correlates with disease progression (Clerici et al, 1997;Swanson et al, 2005). These parameters have not been well defined in HIV-1 C infection.…”

Section: Introductionmentioning

confidence: 99%

Correlation of immune activation with HIV-1 RNA levels assayed by real-time RT-PCR in HIV-1 subtype C infected patients in Northern India

Agarwal

Sankaran

Vajpayee

et al. 2007

Journal of Clinical Virology

View full text Add to dashboard Cite

Background-Assays with specificity and cost effectiveness are needed for the measurement of HIV-1 burden to monitor disease progression or response to anti-retroviral therapy (ART) in HIV-1 subtype C infected patients.Objectives-The objective of this study was to develop and validate an affordable; one step Real-Time RT-PCR assay with high specificity and sensitivity to measure plasma HIV-1 loads in HIV-1 subtype C infected patients.Results-We developed an RT-PCR assay to detect and quantitate plasma HIV-1 levels in HIV-1 subtype C infected patients. An inverse correlation between plasma viral loads (PVL) and CD4 + T-cell numbers was detected at all CDC stages. Significant correlations were found between CD8+ T-cell activation and PVL, as well as with the clinical and immunological status of the patients.Conclusions-The RT-PCR assay provides a sensitive method to measure PVL in HIV-1 subtype C infected patients. Viral loads correlated with immune activation and can be used to monitor HIV care in India.

show abstract

“…In contrast, bDNA (Versant v3.0) and NASBA (EasyQ) assays are considerably less reliable for accurate viral load measurements across HIV clades (Bourlet et al, 2011;Church et al, 2011;Katsoulidou et al, 2011;Swanson et al, 2007;Tang et al, 2007). In summary, available data indicates that HIV-1 assays targeting the highly conserved pol integrase region of the HIV-1 genome may be subject to less variability than assays targeting the gag gene (Geelen et al, www.intechopen.com HIV-1 Diversity and Its Implications in Diagnosis, Transmission, Disease Progression, and Antiretroviral Therapy 179 2003; Swanson et al, 2005;Swanson et al, 2006;Swanson et al, 2007). As HIV genetic diversity evolves, evaluations of all commercially licensed HIV-1 viral load assays should be performed regularly in populations with patients infected with all viral subtypes.…”

Section: Viral Load Assaysmentioning

confidence: 99%

“…Several comparative studies have shown that the sensitivity and specificity of viral load assays varies depending on HIV-1 group or subtype, especially in non-B subtypes, complex recombinant forms and groups O, N, and P viruses (Bourlet et al, 2011;Church et al, 2011 Geelen et al, 2003;Gottesman et al, 2006;Holguin et al, 2008;Katsoulidou et al, 2011;Plantier et al, 2009b;Rouet et al, 2010;Scott et al, 2009;Swanson et al, 2005;Swanson et al, 2006;Swanson et al, 2007;Tang et al, 2007;Wirden et al, 2009;Xu et al, 2008). However, the newer quantitative real-time PCR (qRT-PCR) methods (i.e., m2000rt Abbot Real Time HIV-1 Assay or Cobas AmpliPrep/COBAS TaqMan) showed a higher performance on HIV viral load testing of patients with subtype B as well as patients with non-B subtype infections (Bourlet et al, 2011;Church et al, 2011;Katsoulidou et al, 2011;Swanson et al, 2007;Tang et al, 2007).…”

Section: Viral Load Assaysmentioning

confidence: 99%

HIV-1 Diversity and Its Implications in Diagnosis, Transmission, Disease Progression, and Antiretroviral Therapy

Bártolo¹,

Taveira²

2012

Genetic Diversity in Microorganisms

View full text Add to dashboard Cite

Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT

Cited by 102 publications

References 54 publications

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

Correlation of immune activation with HIV-1 RNA levels assayed by real-time RT-PCR in HIV-1 subtype C infected patients in Northern India

HIV-1 Diversity and Its Implications in Diagnosis, Transmission, Disease Progression, and Antiretroviral Therapy

Contact Info

Product

Resources

About